U.S. State Issues

• PPTA Letter to the Chairmen of the Joint Committee on Public Health In Massachusetts Regarding Support for HB 2098, an Act Relevant to the Treatment of Hemophilia (November 2009)
• PPTA Letter to Illinois Governor Pat Quinn Regarding Support for the Bleeding Disorders Community (May 2009)
• PPTA Comment Letter to the DC Department of Health; Proposed Rule Creating Chapter 17, Pharmaceutical Education Program, of Title 22, of the District of Columbia Municipal Regulations (August 2008)

• PPTA Support Letter to the Massachusetts Senate Health Care Financing Committee; H. 4574 Vital Legislation for the Bleeding Disorders Community (July 2008)
• PPTA Support Letter to the California Assembly Budget Sub-Committee on Proposed Budget Trailer Bill Language (May 2008)
• PPTA Comment Letter to the California Senate Health Committee; SB 1594, the “Hemophilia Standards of Care Act”  (March 2008)
• PPTA Comment Letter to the California Board of Pharmacy Regarding Delay Implementation of California’s Pedigree Requirements (March 2008)
• PPTA Comment Letter to the California Board of Pharmacy Regarding Pedigree Law Implementation (December 2007)
• State of Alabama Response to PPTA on Alabama Medicaid Program Decision to Implement Changes In Reimbursement of Hemophilia Factor VIII Therapies (November 2007)
• PPTA Letter to Office of Pharmacy in State of West Virginia on Reimbursement for A1P1 Products (October 2007)
• PPTA Support Letter for H.2155 and H.2071 on Vital Legislation for the Bleeding Disorders Community in Massachusetts (September 2007)
• PPTA Letter to Pennsylvania House Insurance Committee Chairman for the Enactment of HB 1105, the "Hemophilia Standards of Care Act" (June 2007)
• PPTA Comment Letter to Arkansas Medicaid Policy Program on Arkansas Hemophilia Management Program (June 2007)
• PPTA Memo to Members Outlining OIG Report Summary Related to Average Manufacturer Price (May 2007)
• PPTA Comment Letter to Arizona Senate Committee on Health – IVIG hearing Update (March 2007)
• PPTA Comment letter on Deficit Reduction Act of 2005 (February 2007)
• PPTA Comment Letter to State of Alabama on Medicaid Program Decision to Implement Public Health Service Based Pricing for Reimbursement of Hemophilia Factor VIII Therapies (January 2007)  

• PPTA remains committed to preventing cost containment measures from impacting patient access to life-saving therapies. Payers frequently use cost containment measures to reduce the impact of rising health care costs. Common strategies include reducing pharmacy reimbursement, requiring patient cost-sharing, and single source provider agreements.
• West Virginia Office of Pharmacy Services Response to PPTA on Reimbursement rate for alpha-1 proteinase inhibitors (December 2007)
• PPTA Comment Letter to the Florida Chairman, HHS Appropriations Regarding Support the Alpha One Screening and Detection Program (April 2008)
• PPTA Comment Letter to the Kentucky Office of Legal Services on the Department for Medicaid Services’ Proposed Administrative Regulation Hemophilia Treatment Reimbursement and Coverage Via the 340B Drug Pricing Program 907 K.A.R. 3:205 (September 2008)
• Impact of Medicaid Reimbursement - Issue Brief (October 2007)
• PPTA Memo to Member Companies Summarizing Final Rule Implementing the Average Manufacturer Price Provisions of the Deficit Reduction Act of 2005 (July 2007)

• There are more than 45 million individuals in the United States that lack health insurance. Many states are discussing healthcare reform to address the problem of the uninsured in their state. PPTA will actively participate in these discussions to ensure that the unique health care needs of plasma protein therpaies consumers are addressed.
• PPTA Comments on Texas Medicaid Reform Proposal (December 2007)
• PPTA Memo Summarizing California Healthcare Reform Update (July 2007)

• Minnesota SB339: Standards of Care Bill 2009. Descriptions of alpha-1 antitrypsin deficiency, primary immunodeficiency diseases and von Willebrand Disease.
• Minnesota: Proclamation the Month of May 2008 as Plasma Protein Therapies Month
• Minnesota: SF2290 and HF3013, “A bill for an act relating to health; requiring coverage of plasma protein treatments; amending Minnesota Statutes 2006, section 256B.0625, by adding a subdivision; proposing coding for new law in Minnesota Statutes, chapter 144A
• Florida – Senate Resolution Recognizing April 2007 as Plasma Protein Therapies Month
• Maine – Joint Resolution Establishing March as Access to Plasma Protein Therapies Month
• Minnesota – Proclamation the month of May 2007 as Plasma Protein Therapies Month
• Texas – State Resolution Recognizing June 2007 Be Recognized as IVIG Awareness Month

• In addition to the following information, consumer groups also should visit the State Advocacy Handbook. PPTA developed this resource to help consumer groups advocated for patient access in their states and to provide information about key issues facing users of plasma protein therapies.